Active, not recruitingPhase 2NCT04595825
CM-101 in PSC Patients -The SPRING Study
Studying Primary sclerosing cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ChemomAb Ltd.
- Principal Investigator
- Matthew Frankel, MDChemomAb Ltd.
- Intervention
- Anti-human CCL24 monoclonal antibody (CM-101)(biological)
- Enrollment
- 68 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2020 – 2025
Study locations (30)
- Scripps Clinic Torrey Pines - site P83, La Jolla, California, United States
- UC Davis Health System - Midtown Ambulatory Care Center - site P79, Sacramento, California, United States
- Northwestern University - site P77, Chicago, Illinois, United States
- Massachusetts General Hospital - site P95, Boston, Massachusetts, United States
- Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - Liver Center - site P81, Boston, Massachusetts, United States
- Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park - site P82, Germantown, Tennessee, United States
- Methodist Dallas Medical Center - site P72, Dallas, Texas, United States
- Virginia Commonwealth - site P94, Richmond, Virginia, United States
- Klinikum der Johann Wolfgang Goethe-Universitaet - site P42, Frankfurt am Main, Germany
- Universitätsklinikum Hamburg-Eppendorf (UKE) - site P47, Hamburg, Germany
- Medizinische Hochschule Hannover (MHH) - site P41, Hanover, Germany
- Soroka MC - site P23, Beersheba, Israel
- Shamir Medical Center (Assaf Harofeh) - site P28, Be’er Ya‘aqov, Israel
- Carmel - site P27, Haifa, Israel
- Rambam MC - site P22, Haifa, Israel
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04595825 on ClinicalTrials.govOther trials for Primary sclerosing cholangitis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07567274DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine InjuryLeading Edge Clinic
- RECRUITINGPHASE3NCT07387549A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisIpsen
- RECRUITINGPHASE1NCT07229911A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)Takeda
- RECRUITINGPHASE2NCT06699121A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSCLISCure Biosciences
- RECRUITINGPHASE2NCT06905054Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver TransplantationMayo Clinic
- RECRUITINGNANCT06865924Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing CholangitisFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT06297993Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)PSC Partners Seeking a Cure
- RECRUITINGPHASE2NCT06286709FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitisUniversity of Birmingham